Oncology & Hematology Coding Alert
Reader Question:
Distinguish Biosimilar and Reference Filgrastim
Published on Fri Dec 23, 2016
You’ve reached your limit of free articles. Already a subscriber? Log in.
Not a subscriber? Subscribe today to continue reading this article. Plus, you’ll get:
Other Articles in this issue of
Oncology & Hematology Coding Alert
- 2017 Update:
Two Key CCI Updates Impact Your Radiation Oncology Coding in 2017
Edits dissolve for dosimetry and 3D planning; new ones apply to IMRT services. With the [...] - ICD-10-CM Review:
Spot the Right Codes for Malignant Neoplasms in the Cord, Cauda, and Cranial Nerves
Cauda equina malignancy has defined code though not all in cranial nerves have specific codes. [...] - E/M Coding:
Follow These Expert Tips For Perfect Prolonged Services Claims
Key: Watch the clock and add up all the time spent on one calendar day. [...] - You Be the Coder:
Check the 48-hour Rule for Anti-emesis with Chemo
Question: Our physician prescribed oral chlorpromazine to a patient who presented for chemotherapy. How can we [...] - Reader Question:
Meet Minimum INR Testing for Warfrin Dose Adjustments
Question: Our physician adjusted the warfarin dose for a patient during follow up in the [...] - Reader Question:
Distinguish Biosimilar and Reference Filgrastim
Question: Our physician administered filgrastim has mentioned no other details for the drug administered. We are [...] - Reader Question:
Target K13.4 for Oral Pyogenic Granuloma
Question: In a patient with a painless rapidly growing lesion in the oral cavity near the [...]
View All
